COMMUNIQUÉS West-GlobeNewswire

RAPPEL – Max Domi, joueur de la LNH, marchera avec des milliers de résidents du Grand Montréal pour trouver une guérison au diabète de type 1
07/06/2019
La Marche pour la guérison du diabète Sun Life FRDJ vise à amasser 5 millions $ pour accélérer le rythme de la recherche et sensibiliser au diabète de type 1 MONTRÉAL, 07 juin 2019 (GLOBE NEWSWIRE) -- Le 9 juin 2019, [...]
Generex Provides Update to Pending 1:1 Stock Dividend
07/06/2019
MIRAMAR, Fla., June 07, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ), in response to the large volume of investor calls, [...]
ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis
07/06/2019
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that it has successfully completed the marketing authorisation procedure for its tree sublingual allergy immunotherapy (SLIT) tablet in 17 European countries. [...]
Resverlogix Announces Closing of $15 Million Offering
07/06/2019
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 07, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is [...]
Better Choice Company Announces Pet CBD Research & Development Partnership in Israel with CannaSoul
07/06/2019
NEW YORK, June 07, 2019 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (OTCQB: BTTR) (the “Company”), an animal health and wellness CBD company, today announced that it has entered into a research and development [...]
TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019
07/06/2019
SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancers New oral approach aimed at disrupting cancer metabolism in metastatic [...]
AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers
07/06/2019
BROOKLYN, N.Y., June 07, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), today announced that both the United States Patent and Trademark Office and the Japan Patent Office [...]
GBT Announces New Employment Inducement Grants
07/06/2019
SOUTH SAN FRANCISCO, Calif., June 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2019, the compensation committee of GBT’s board of directors granted 19 [...]
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions
07/06/2019
AT-001, a novel, potent and selective aldose reductase inhibitor, is expected to start a pivotal study later this year NEW YORK, June 07, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical- [...]
Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting
07/06/2019
Meeting Coverage of 2019 Updated ADA Standards of Medical Care in Diabetes to Include Role of Icosapent Ethyl as a Management Option for Diabetic Patients with Cardiovascular Risks, Based on Landmark REDUCE-IT TM Trial [...]
Data on Albireo’s Odevixibat Presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
07/06/2019
Data support further study of odevixibat across a range of rare cholestatic liver diseases BOSTON, June 07, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease [...]
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
07/06/2019
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in refractory chronic [...]
Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
07/06/2019
Placebo-controlled Phase 3 trial of AXS-05 in MDD on track to start in 2Q 2019 Topline results from both STRIDE-1 Phase 3 trial in TRD and planned placebo-controlled Phase 3 trial in MDD for AXS-05 still anticipated in [...]
Rockwell Medical Announces Adjournment of Annual Meeting of Shareholders
07/06/2019
- Adjournment solely to vote on Delaware reincorporation Proposal 3(a) - - Both leading independent advisory firms have issued favorable recommendations on proposal - WIXOM, Mich., June 07, 2019 (GLOBE NEWSWIRE) -- [...]
Nightstar Therapeutics PLC Completion of Acquisition by Biogen
07/06/2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT [...]
Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
07/06/2019
Nightstar acquisition further bolsters Biogen’s pipeline with the addition of two mid- to late-stage clinical assets as well as preclinical programs CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: [...]
Saniona publishes prospectus relating to the rights issue
07/06/2019
PRESS RELEASE NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION [...]
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology
07/06/2019
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24 th World Congress of Dermatology Cutaneous Lymphoma Meeting will update on latest developments in the field [...]
Acarix participates on the Redeye Growth Day, Monday 10 June 2019
07/06/2019
Acarix participates on the Redeye Growth Day, Monday 10 June 2019 On Monday, June the 10 th at 3.40 PM, Per Persson CEO for Acarix, will be presenting the latest activities and strategic directions for Acarix. The [...]

Pages